Olmesartán Tarbis (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Tarbis, is an angiotensin II receptor blocker presented as a tablet for oral use. It is employed in the management of hypertension in adult patients. GNH USA supplies Olmesartán Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil is an antihypertensive agent that acts on the renin‑angiotensin system to lower blood pressure. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy (adjunct): may slow progression of kidney damage when used with other therapies. - Heart failure (off‑label): sometimes used to support blood‑pressure control in heart‑failure patients. - Stroke prevention (off‑label): contributes to long‑term risk reduction in patients with prior cerebrovascular events.

Olmesartan Medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Back pain

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Bullous pemphigoid

When prescribing Olmesartan Medoxomil, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine and monitor periodically. - Electrolytes: check potassium levels, especially if combined with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Elderly: start at lower dose and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications for additive blood‑pressure effects. - Store at ambient temperature: keep in original packaging ; protect from moisture.

Olmesartan Medoxomil can interact with several medicines that affect blood pressure or renal function.

Major Interactions (Avoid): - Aliskiren combined with any ARB in patients with diabetes or renal impairment. - Potassium‑rich supplements and potassium‑sparing diuretics – risk of hyper‑kalaemia. - Dual ACE‑inhibitor or ARB therapy – increased risk of renal dysfunction.

Moderate Interaction Monitor Closely: - Non‑steroidal anti‑inflammatory NSAIDs – may blunt antihypertensive effect. - Lithium – may increase serum lithium levels. - Cyclosporine – may raise olmens c‑ c  ...  ...   ...  ...  …  …